Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 7/20 | 0.73 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.63 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.63 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.59 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.59 |
| ▸ | AXL | P30530 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | BACE1 | P56817 | 2/20 | 0.55 |
| ▸ | ATR | Q13535 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 4/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | CYP2E1 | P05181 | 3/20 | 0.49 |
| ▸ | KMO | O15229 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29809603 | 1.00 | CYP2A6 (0.73) | CYP2A6LOXL2EPHX2PRMT6MKNK1 | |
| SCHEMBL5216350 | 0.86 | CHRNA7 (0.65) | CYP2A6LOXL2EPHX2PRMT6MKNK1 | |
| SCHEMBL1690457 | 0.85 | CYP2A6 (0.68) | CYP2A6LOXL2EPHX2PRMT6MKNK1 | |
| SCHEMBL30083377 | 0.85 | CYP2A6 (1.00) | CYP2A6LOXL2EPHX2PRMT6MKNK1 | |
| SCHEMBL1720463 | 0.85 | CYP2A6 (1.00) | CYP2A6LOXL2EPHX2PRMT6MKNK1 | |
| SCHEMBL20797575 | 0.83 | CYP2A6 (0.50) | CYP2A6LOXL2EPHX2PRMT6BACE1 | |
| SCHEMBL3187079 | 0.83 | CYP2A6 (0.67) | CYP2A6LOXL2EPHX2PRMT6MKNK1 | |
| SCHEMBL3791745 | 0.82 | LOXL2 (0.60) | LOXL2PRMT6KLKB1CDK8 | |
| SCHEMBL1130071 | 0.81 | EPHX2 (0.63) | CYP2A6EPHX2PRMT6MKNK1MKNK2 | |
| SCHEMBL4581739 | 0.81 | MKNK1 (0.68) | CYP2A6EPHX2PRMT6MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150346-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2024-05-09 | — | — | US | disclosed |
| EP-3452477-B1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B C I PHARMA (BE) | 2023-09-13 | — | — | EP | disclosed |
| US-20220402883-A1 | COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION | ARRAKIS THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220281860-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | ARRAKIS THERAPEUTICS, INC. | 2022-09-08 | — | — | US | disclosed |
| WO-2022161420-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2022-08-04 | — | — | WO | disclosed |
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | B.C.I. PHARMA (BE) | 2022-02-01 | — | — | US | disclosed |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2019-05-02 | — | — | US | disclosed |
| CN-104837832-A | GDF-8 inhibitors | RIGEL PHARMACEUTICALS INC | 2015-08-12 | — | — | CN | disclosed |
| EP-2828253-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2015-01-28 | — | — | EP | disclosed |
| WO-2013142307-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS (US) | 2013-09-26 | — | — | WO | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| US-20080242666-A1 | 1-6-Substituted (3R,6R)-3-(2,3-Dihydro-1H-Inden-2-Yl)-2,5-Piperazinedione Derivatives as Oxytocin Receptor Antagonists For the Treatment of Preterm Labour, Dysmenorrhea and Endometriosis | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| US-20080242666-A1 | 1-6-Substituted (3R,6R)-3-(2,3-Dihydro-1H-Inden-2-Yl)-2,5-Piperazinedione Derivatives as Oxytocin Receptor Antagonists For the Treatment of Preterm Labour, Dysmenorrhea and Endometriosis | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| US-20080242666-A1 | 1-6-Substituted (3R,6R)-3-(2,3-Dihydro-1H-Inden-2-Yl)-2,5-Piperazinedione Derivatives as Oxytocin Receptor Antagonists For the Treatment of Preterm Labour, Dysmenorrhea and Endometriosis | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| CN-101128439-A | 1,6 - substituted (3r,6r) -3- (2,3-dihydro-1h-inden-2-yl)-2,5-piperazinedione derivatives as oxytocin receptor antagonists for the treatment of pre-term labour, dysmenorrhea and endometriosis | GLAXO GROUP LTD (GB) | 2008-02-20 | — | — | CN | disclosed |
| EP-1831183-A1 | 1,6-SUBSTITUTED (3R,6R)-3-(2,3-DIHYDRO-1H-INDEN-2-YL)-2,5-PIPERAZINEDIONE DERIVATIVES AS OXYTOCIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PRE-TERM LABOUR, DYSMENORRHEA AND ENDOMETRIOSIS | GLAXO GROUP LIMITED (GB) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006067462-A1 | 1,6 - SUBSTITUTED (3R,6R) -3- (2,3-DIHYDRO-1H-INDEN-2-YL)-2,5-PIPERAZINEDIONE DERIVATIVES AS OXYTOCIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PRE-TERM LABOUR, DYSMENORRHEA AND ENDOMETRIOSIS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006067462-A1 | 1,6 - SUBSTITUTED (3R,6R) -3- (2,3-DIHYDRO-1H-INDEN-2-YL)-2,5-PIPERAZINEDIONE DERIVATIVES AS OXYTOCIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PRE-TERM LABOUR, DYSMENORRHEA AND ENDOMETRIOSIS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | ADK, TNNI3K, TNK2 | CYP2A6 3933/4885LOXL2 2209/4885EPHX2 2818/4885 |
| US-20240150346-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | TLR7, TLR1, TLR8 | CYP2A6 621/4885LOXL2 1342/4885EPHX2 2286/4885 |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ADK, TNNI3K, TNK2 | CYP2A6 3933/4885LOXL2 2209/4885EPHX2 2818/4885 |
| US-20080242666-A1 | 1-6-Substituted (3R,6R)-3-(2,3-Dihydro-1H-Inden-2-Yl)-2,5-Piperazinedione Derivatives as Oxytocin Receptor Antagonists For the Treatment of Preterm Labour, Dysmenorrhea and Endometriosis | OXTR, OPRL1, GPER1 | CYP2A6 462/4885LOXL2 3440/4885EPHX2 2040/4885 |
| US-20220281860-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | NSUN3, NSUN2, POLRMT | CYP2A6 3354/4885LOXL2 2637/4885EPHX2 3332/4885 |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | CYP2A6 333/4885LOXL2 1544/4885EPHX2 701/4885 |
| US-20220402883-A1 | COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION | NSUN3, NSUN2, METTL16 | CYP2A6 4642/4885LOXL2 3924/4885EPHX2 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.